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Psoriasis as a chronic inﬂammatory disease often requires effective long-term treatment; a comprehensive
systematic evaluation of efﬁcacy and safety of systemic long-term treatments in patients with moderate-to-severe
psoriasis is lacking. Twenty-ﬁve randomized clinical trials were included. Results were pooled and quality of
evidence was assessed using GRADE (Grading of Recommendations Assessment, Development and Evaluation).
With respect to PASI 75 (psoriasis area and severity index), pooled risk ratios for inﬂiximab (13.07, 95%
conﬁdence interval (CI): 8.60–19.87), secukinumab (11.97, 95% CI: 8.83–16.23), ustekinumab (11.39, 95% CI: 8.94–
14.51), adalimumab (8.92, 95% CI: 6.33–12.57), etanercept (8.39, 95% CI: 6.74–10.45), and apremilast (5.83, 95% CI:
2.58–13.17) show superiority of biologics and apremilast in long-term therapy compared with placebo. With
respect to the addressed safety parameters, no differences were seen between adalimumab, etanercept, or
inﬂiximab versus placebo. No placebo-controlled data on conventional treatments was identiﬁed. Head-to-head
studies showed superior efﬁcacy of secukinumab and inﬂiximab versus etanercept and of inﬂiximab versus
methotrexate. A clear ranking is limited by the lack of long-term head-to-head trials. From the available evidence,
inﬂiximab, secukinumab, and ustekinumab are the most efﬁcacious long-term treatments. Data on conventionals
are insufﬁcient. Further head-to-head comparisons and studies on safety and patient-related outcomes are
needed to draw more reliable conclusions.
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INTRODUCTION
Psoriasis vulgaris is a chronic inﬂammatory disease with a
substantial impact on the patients’ quality of life (Lee et al.,
2010). Most studies focus on short-term induction periods.
Placebo-controlled long-term studies are rare, and performing
a meta-analysis of long-term data a challenge. However, to
control and treat psoriasis, an effective and safe long-term
therapy is required. In the current guidelines on systemic
antipsoriatic treatment, four different conventional and four
different biological therapies have been included (Pathirana
et al., 2009; Nast et al., 2011). Recently, secukinumab, an
IL-17 antagonist, and apremilast, an inhibitor of phos-
phodiesterase 4, were approved and/or recommended by
the US Food and Drug Administration (Food and Drug
Administration, 2014,2015) and/or the Committee for
Medicinal Products for Human Use of the European
Medical Agency as new treatment options for psoriasis
(European Medicines Agency, 2014a, b).
Existing systematic reviews and meta-analyses on the
treatment of psoriasis have focused on induction therapy or
do not include the recently approved treatments (Spuls et al.,
1998; Woolacott et al., 2006; Schmitt and Wozel, 2009;
Lucka et al., 2012; Liu et al., 2014; Meng et al., 2014;
Schmitt and Wozel, 2014a). In addition, existing reviews
have not used the already established GRADE (Grading of
Recommendations Assessment, Development and Evaluation)
approach to assess the quality of included studies.
PASI (psoriasis area and severity index) is the most widely
used score in psoriasis trials, making meta-analysis of existing
trials possible. The Dermatology Life Quality Index (DLQI) is a
widely accepted patient-oriented score used in many trials. In
psoriasis trials in general, the reporting of safety is very little
standardized. For this reason, safety aspects have been
neglected in existing reviews. The committee for the update
of the European psoriasis guidelines has selected the out-
comes: (a) ‘number of patients with at least one adverse event
(AE)’, (b) ‘number of patients with at least one serious AE
(SAE)’, and (c) ‘withdrawal due to AE’ as relevant and
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sufﬁciently standardized outcomes to be extracted and
considered for the assessment of treatments in the European
Guidelines (consultation draft, date: 26 January 2015).
The aim of this systematic review is to provide a
comprehensive overview about evidence on the efﬁcacy
and/or safety of systemic treatments for moderate-to-severe
psoriasis in long-term therapy in adult patients based on
randomized controlled trials (RCTs).
RESULTS
Systematic search yielded 5,663 results. After deduplication,
4,102 records remained and were screened by title and
abstract. Three additional references were retrieved by hand
search through reference lists. Overall, 48 articles were
assessed for eligibility in full text, whereas 31 publications
reporting on 25 independent RCTs met the inclusion criteria
(Figure 1). Reasons for exclusion of articles are listed in
Supplementary Material Table 1 online.
Twenty-ﬁve studies with two to four study groups and a
total of 11,279 randomized patients were included in the
analysis. Ten trials were initially placebo-controlled, 11 trials
had placebo and active treatment as control, and four trials
had at least one active treatment as control. Three studies
remained placebo-controlled until week 24 (Gottlieb et al.,
2003; Reich et al., 2005; Asahina et al., 2010) and were
pooled to calculate a mean ‘placebo response’, which was
used as a model for trials without long-term placebo control.
The study sample size varied from 48 to 1,306. Thirty-one
percent of all study subjects were female. All included trials
performed intention-to-treat analysis.
No studies investigating fumaric acid esters and cyclosporine
A (CsA) in long-term treatment were available. Long-term data
of direct comparisons of systemic therapies of up to 24 weeks
were available for etanercept, inﬂiximab, secukinumab, metho-
trexate (MTX), and acitretin. Detailed data on all included
studies are presented in Supplementary Table 2.
There is only one included head-to-head trial reporting
efﬁcacy data beyond 28 weeks of treatment for the com-
parison with etanercept and secukinumab (Langley et al.,
2014) (see Supplementary Material, Table 3). All summary of
ﬁnding tables are presented as part of the Supplemental
Material (Table 4).
Risk of bias
The risk of bias among the included studies was partly
heterogeneous, rated with low risk or unclear risk of bias. Of
the 25 included RCTs, 13 (52%) reported an adequate
randomization method and 14 (56%) supplied sufﬁcient
information to assess whether allocation concealment was
properly ensured. In three studies (12%), the blinding
of participants and personnel was insufﬁcient (open
(Barker et al., 2011) or single blind (Gisondi et al., 2008; de
Vries et al., 2013) study design). In 21 studies (84%), the
risk of attrition bias was low, as incomplete outcome data
were sufﬁciently addressed. The risk of reporting bias was low
in most of the studies (80%). The risk of bias for each study is
presented in Supplementary Material Figure 1.
Comparison of monotherapy versus placebo (at weeks 24–28)
Placebo-controlled studies were identiﬁed for all biologics and
for apremilast but not for conventional treatments. These drugs
have been shown to be effective in long-term therapy compared
with placebo up to week 28. With respect to the addressed
safety parameters, no differences were seen between the
biologics and placebo. Data on PASI 75 response are presented
in Figure 2 (Forest plots of other outcomes are available in
Supplementary Material Figure 2).
Efﬁcacy: assessor-oriented scores
PASI 75. All biologics and apremilast showed superior efﬁcacy
compared with placebo with respect to their PASI 75 response
(Figure 2).
The pooled risk ratio (RR) for inﬂiximab (Reich et al.,
2005,2006; Menter et al., 2007; Feldman et al., 2008; Torii
et al., 2010; Yang et al., 2012), secukinumab (Langley et al.,
2014), ustekinumab (Leonardi et al., 2008; Papp et al., 2008;
Tsai et al., 2011; Igarashi et al., 2012; Zhu et al., 2013;
Janssen et al., 2014a,b), adalimumab (Gordon et al., 2006;
Menter et al., 2008; Asahina et al., 2010), etanercept (Gottlieb
et al., 2003; Leonardi et al., 2003; Krueger et al., 2005; Papp
et al., 2005; Tyring et al., 2006,2007; van de Kerkhof et al.,
2008; Bagel et al., 2012; Langley et al., 2014), and apremilast
(Papp et al., 2012) are 13.07 (95% conﬁdence interval (95%
CI): 8.60, 19.87, I2=0%), 11.97 (95% CI: 8.83, 16.23,
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Figure 1. Identiﬁcation of literature.
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I2= 0%), 11.39 (95% CI: 8.94, 14.51, I2= 0%), 8.92 (95% CI:
6.33, 12.57, I2= 8%), 8.39 (95% CI: 6.74, 10.45, I2= 0%),
and 5.83 (95% CI: 2.58, 13.17), respectively, with low quality
of evidence.
PASI 90. A higher probability to achieve a PASI 90 response
compared with placebo at weeks 24–28 was seen with
secukinumab (RR 40.15 (95% CI: 20.97, 76.89), I2=0%)
(Langley et al., 2014), ustekinumab (RR 31.63 (95% CI: 19.43,
51.51), I2=0%) (Leonardi et al., 2008; Papp et al., 2008; Tsai et al.,
2011; Igarashi et al., 2012; Zhu et al., 2013; Janssen et al., 2014a,
b), inﬂiximab (RR 31.00 (95% CI: 13.45, 71.46), I2=0%) (Reich
et al., 2005, 2006; Menter et al., 2007; Feldman et al., 2008; Torii
et al., 2010; Langley et al., 2014), adalimumab (RR 23.17 (95% CI:
12.51, 42.91), I2 = 0%) (Gordon et al., 2006; Menter et al., 2008;
Asahina et al., 2010), etanercept (RR 19.14 (95% CI: 11.59, 31.60),
I2=0%) (Gottlieb et al., 2003; Leonardi et al., 2003; Tyring et al.,
2006,2007; van de Kerkhof et al., 2008; Bagel et al., 2012), and
apremilast (RR 13.00 (95% CI: 1.74, 97.25)) (Papp et al., 2012).
The quality of the evidence for all results was low.
PGA ‘clear/almost clear’. Based on PGA (Physician Global
Assessment) ‘clear/almost clear’, the biologics and apremilast are
superior to placebo. The RRs are 13.13 (95% CI: 8.45, 20.38,
I2= 0), 9.91 (95% CI: 7.76, 12.66, I2=0), 9.84 (95% CI: 7.25,
13.36, I2= 0%), 8.06 (95% CI: 5.89, 11.04, I2=0), 7.16 (95% CI:
5.35, 9.57, I2=0), and 5.00 (95% CI: 2.19, 11.41) for inﬂiximab
(Reich et al., 2005, 2006; Menter et al., 2007; Feldman et al.,
2008; Yang et al., 2012), ustekinumab (Leonardi et al., 2008;
Papp et al., 2008; Tsai et al., 2011; Zhu et al., 2013; Janssen
et al., 2014a,b), secukinumab (Langley et al., 2014), adalimumab
(Gordon et al., 2006; Menter et al., 2008; Asahina et al., 2010),
etanercept (Gottlieb et al., 2003; Leonardi et al., 2003; van de
Kerkhof et al., 2008; Bagel et al., 2012; Langley et al., 2014), and
apremilast (Papp et al., 2012), respectively. All results have been
assigned a low quality of evidence.
Figure 2. Forest plot: Verum versus placebo—PASI 75 at weeks 24–28. CI, conﬁdence interval; b.i.d., twice daily; b.i.w., twice weekly; EOW, every other week;
PASI, psoriasis area and severity index; q.w., once weekly; w, week.
A Nast et al.




Absolute reduction in mean DLQI. With a mean difference
(MD) in absolute reduction in mean DLQI of 9.80 (95%
CI: 8.19, 11.41), inﬂiximab is statistically signiﬁcantly superior
to placebo in long-term treatment (high quality) (Reich et al.,
2005,2006).Compared with placebo, a higher reduction in
absolute DLQI in the long-term treatment was found for
adalimumab 80mg every other week (MD 5.70 (95% CI:
3.13, 8.27), moderate quality) (Asahina et al., 2010),
adalimumab with a loading dose of 80mg and following 40mg
every other week (MD 4.20 (95% CI: 1.54, 6.86), low quality)
(Asahina et al., 2010), and for adalimumab 40mg every
other week (MD 3.30 (95% CI: 0.56, 6.04), low quality)
(Asahina et al., 2010). However, the effects were small for the
last two dosing regimens.
Figure 2. Continued
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Percentage reduction in mean DLQI. Etanercept 50mg twice
weekly (b.i.w.) has been shown to be superior to placebo in long-
term treatment with an MD in percentage DLQI reduction in
57.00 (95% CI: 38.52, 75.48, high quality) (Gottlieb et al., 2003).
Safety
Patients with at least one AE. After long-term treatment, no
differences were found between adalimumab and placebo in the
number of patients with at least one AE (RR 1.04 (95% CI: 0.93,
1.16), moderate quality) (Asahina et al., 2010) and between
inﬂiximab and placebo (RR 1.15 (95% CI: 0.99, 1.34), moderate
quality) (Reich et al., 2005, 2006).
Patients with at least one SAE. Compared with placebo, no
differences in the risks of SAE were shown for adalimumab (RR
0.75 (95% CI: 0.14, 3.95), low quality) (Asahina et al., 2010),
etanercept 50mg once weekly (q.w.) (RR 0.64 (95% CI: 0.11,
3.70), moderate quality) (Gottlieb et al., 2003), and inﬂiximab
(RR 2.16 (95% CI: 0.65, 7.17), I2=0%, moderate quality) (Reich
et al., 2005,2006; Yang et al., 2012).
Withdrawal due to AE. In comparison with placebo, no
statistically signiﬁcant differences in withdrawal due to AE in
long-term treatment were found for adalimumab (RR 0.87
(95% CI: 0.24, 3.23), low quality) (Asahina et al., 2010),
etanercept 50mg q.w. (RR 0.32 (95% CI: 0.07, 1.53), moderate
quality) (Gottlieb et al., 2003), and inﬂiximab (RR 1.38 (95% CI:
0.55, 3.46), moderate quality) (Reich et al., 2005, 2006).
Head-to-head comparisons of systemic treatments (at weeks
24–26)
Five studies were identiﬁed providing long-term data of direct
comparisons (see Supplementary Material Figure 3).
Acitretin 0.4 mg kg− 1 once daily (q.d.) versus etanercept 25mg
b.i.w. After long-term treatment, no statistically signiﬁcant
differences were found between acitretin and etanercept with
respect to PASI 75 (RR 0.66 (95% CI: 0.29, 1.49)) and with
respect to the number of patients with at least one AE (RR 5.48
(95% CI: 0.28, 107.62), very low quality for both outcomes)
(Gisondi et al., 2008).
Acitretin 0.4 mg kg− 1 q.d. versus combination of acitretin 0.4
mg kg− 1 q.d. and etanercept 25mg q.w. No differences were
found between acitretin monotherapy and acitretin in combina-
tion with etanercept with respect to PASI 75 (RR 0.68 (95% CI:
0.29, 1.57)) and in the number of patients with at least one AE
(RR 1.80 (95% CI: 0.18, 18.21), very low quality for both
outcomes) (Gisondi et al., 2008).
Etanercept 25mg b.i.w. versus combination of acitretin 0.4
mg kg− 1 q.d. and etanercept 25mg q.w. There are no
differences in PASI 75 response between etanercept combined
with acitretin and etanercept monotherapy after long-term
treatment period (RR 1.02 (95% CI: 0.51, 2.04)). With respect
to the number of patients with at least one AE, it is uncertain
whether there is any difference (RR 0.28 (95% CI: 0.01, 6.38).
The quality of evidence is very low for both outcomes (Gisondi
et al., 2008).
Etanercept 50mg b.i.w. for 12 weeks followed by 50mg kg− 1
q.w. versus combination of etanercept 50mg b.i.w./q.w. and
MTX 7.5–15mg q.w. After long-term treatment, statistically
signiﬁcant differences with a small effect were observed in favor
of the combination etanercept/MTX based on PASI 75 (RR 0.78
(95% CI: 0.69, 0.88), low quality), PASI 90 (RR 0.64 (95% CI:
0.51, 0.78), moderate quality), and PGA ‘clear/almost clear’ (RR
0.76 (95% CI: 0.66, 0.88), low quality). In contrast, a slightly
increased risk for the occurrence of at least one AE was seen with
the combination (RR 0.80 (95% CI: 0.70, 0.91), moderate
quality), whereas no statistically signiﬁcant difference was found
for the number of patients with at least one SAE (RR 1.50 (95% CI:
0.25, 8.90), low quality) (Gottlieb et al., 2012).
Etanercept 50mg b.i.w. versus inﬂiximab 5mg kg− 1. After
long-term treatment, etanercept was inferior to inﬂiximab based
on PASI 75 (RR 0.48 (95% CI: 0.26, 0.89), moderate quality)
(de Vries et al., 2013).
Etanercept 50mg b.i.w./q.w. versus secukinumab 150–300mg
monthly. After long-term treatment, there are small statistically
signiﬁcant differences in favor of secukinumab 150mg based on
PASI 75 (RR 0.80 (95% CI: 0.72, 0.89), moderate quality), PASI
90 (RR 0.67 (95% CI: 0.57, 0.79), high quality), and PGA ‘clear/
almost clear’ (RR 0.74 (95% CI: 0.64, 0.86), moderate quality)
(Langley et al., 2014). Secukinumab 300mg is superior to
etanercept based on PASI 75 (RR 0.72 (95% CI: 0.65, 0.79),
moderate quality), PASI 90 (RR 0.54 (95% CI: 0.46, 0.63), high
quality), and PGA ‘clear/almost clear’ (RR 0.61 (95% CI: 0.53,
0.69), high quality) (Langley et al., 2014).
MTX 15–20 mg q.w. versus inﬂiximab 5mg kg− 1. MTX is
inferior to inﬂiximab in long-term treatment based on PASI 75
(RR 0.40 (95% CI: 0.33, 0.49)), PASI 90 (RR 0.29 (95% CI: 0.21,
0.41)), and PGA ‘clear/almost clear’ (RR 0.38 (95% CI: 0.31,
0.48), moderate quality for all outcomes) (Barker et al., 2011).
With respect to quality of life, MTX and inﬂiximab showed a
percentage reduction in DLQI of 62% and 84%, respectively.
Because of missing measures of variance, no effect estimate was
calculated (Barker et al., 2011).
DISCUSSION
This systematic review summarizes the evidence for efﬁcacy
and safety of systemic drugs in long-term treatment of
moderate-to-severe psoriasis.
Placebo-controlled studies could be identiﬁed for adalimu-
mab, etanercept, inﬂiximab, secukinumab, ustekinumab, and
apremilast. Based on low quality of evidence, all biologics
and apremilast have been shown to be clinically effective in
long-term therapy compared with placebo. Patient relevant
outcomes support this ﬁnding with high to low quality of
evidence. With respect to the addressed safety outcomes,
none of the results showed a statistically signiﬁcant difference
for adalimumab, etanercept, or inﬂiximab compared with
placebo. However, a trend of a less favorable safety proﬁle of
inﬂiximab over placebo can be assumed from these data.
For secukinumab, ustekinumab, and apremilast, no data for
the selected safety outcomes were available.
Head-to-head trials allow a much better direct comparison
of efﬁcacy and safety. However, the number of direct long-
term comparisons is limited. With respect to efﬁcacy, based
on PASI 75, superiority of secukinumab over etanercept, of
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inﬂiximab over MTX (dosages of 15–20mg), and of inﬂiximab
over etanercept was shown in head-to-head trials of at least
24 weeks (moderate quality of evidence). As our addressed
safety parameters were not provided in these studies, no
conclusion with respect to safety was possible.
In head-to-head comparisons, the combination of etaner-
cept plus methotrexate has been found to be superior to
etanercept monotherapy with a low to moderate quality of
evidence. This effect was accompanied by a slight increase in
AEs. Acitretin as a combination partner to etanercept low dose
was shown to have some dose sparing potential compared
with monotherapy with high-dose etanercept.
For comparison of the other interventions, only indirect
comparisons can be carried out. Summarizing the data from the
indirect comparison for PASI 75 responses, the best results were
seen for inﬂiximab, secukinumab, and ustekinumab followed
by adalimumab and etanercept. Apremilast showed the lowest
PASI 75 response rate. Indirect comparisons of the DLQI data
underline the superiority of inﬂiximab over adalimumab. This
ranking has been associated with limited strength as for indirect
comparisons the assumption of clinical and methodological
similarity of the included studies cannot be completely assured.
Summarizing safety data is a critical issue; however, it is
highly limited by feasibility due to a lack of standardised
reporting. Further harmonization of reporting should be pursued;
an excellent approach to harmonizing outcome reporting has
been carried out for eczema and could be initiated for psoriasis
safety reporting as well (Schmitt et al., 2014b). A Cochrane
review investigated the safety of biologic treatments in any
indication, including non-antipsoriatic treatments such as
abatacept and rituximab. The review showed an increased risk
of tuberculosis reactivation (odds ratio 4.68, 95% CI: 1.18–
18.60) compared with control. The rates of SAE, serious infec-
tions, lymphoma, and congestive heart failure were not signiﬁ-
cantly different. Pooling all these different biologics and different
populations into one group is questionable (Singh et al., 2011).
Patient registries are another possible approach to generate
long-term data on efﬁcacy and especially safety. Gniadecki
et al. (2015) have published drug survival data from Danish
psoriasis registry (DERMBIO), which showed longer drug
survival on ustekinumab compared with the anti-TNF agents.
Similar results were found by van den Reek et al. (2015) in the
Dutch Bio-CAPTURE network, with better overall drug survival
of ustekinumab over etanercept and a trend over adalimumab.
Limitations
In most of the long-term studies, the placebo groups were
discontinued after induction. We performed an imputation
approach to make long-term efﬁcacy data of the drugs derived
from original placebo-controlled studies suitable for meta-
analyses. In this imputation approach, we calculated a mean
placebo response of efﬁcacy outcomes based on available
placebo-controlled trials. The original sample size of the
placebo group was also considered. We are aware that this
imputation approach has been associated with uncertainties;
consequently, we downgraded the quality of evidence.
The assessment of safety remains a challenge. Reporting
needs to be more standardised. Even when using the very
broad categories number of patients with ‘at least one AE’, ‘at
least one SAE’, and ‘withdrawal due to AE’, evidence is strongly
limited. As we could not make assumptions on occurrence of
AEs during long-term placebo treatment, imputations of
placebo data for safety outcomes were not performed. In
addition, among biologics, data reported in publications on
ustekinumab and secukinumab were not suitable for analyzing
our predeﬁned safety outcomes, and conclusions on potential
harms based on these parameters could not be drawn.
More long-term head-to-head trials are needed to allow for
comparisons of efﬁcacy and safety with a higher validity. The
RCT setting is preferable, as it generates the more robust data.
Additional data will be generated from the ongoing patient
registers providing information on safety and drug survival
rates in the general patient population.
MATERIALS AND METHODS
This systematic review and meta-analysis was conducted in
accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) statement (Moher et al.,
2009). The selection of databases, eligibility criteria, outcomes of
the review, and analyses methods were deﬁned a priori in an internal
protocol. Study selection, data extraction, and quality assessment
were performed independently by two assessors. Any differences
were solved by discussion and mutual agreement.
Predeﬁned eligibility criteria
Published RCTs were included if they investigated one of the
following treatments in commonly used dosages: acitretin, adalimu-
mab, apremilast, CSA, etanercept, fumaric acid ester, inﬂiximab,
MTX, secukinumab, or ustekinumab. Comparison had to be done
versus placebo, versus another included active treatment, or versus a
combination of two included treatments. Data had to be available for
a treatment duration of at least 24 weeks. Patient population
consisted of adults suffering from moderate-to-severe plaque-type
psoriasis. Studies had to report at least one efﬁcacy or safety outcome
for long-term treatment. No language restrictions were applied.
Information sources and search
Systematic literature searches were conducted in Medline, Medline in
Process, and Embase using OvidSP platform. In addition, the Cochrane
Library was searched via its online search platform. Search dates were
from inception to 5 January 2015. The search strategy for Medline is
presented in Supplementary Material Table 5. In addition, reference
lists of relevant reviews and included studies were screened.
Study selection and data extraction
After exclusion of duplicates, titles and abstracts were screened for
inclusion and exclusion. Potentially relevant articles were checked in
full text for inclusion.
Study characteristics (e.g. medication and dosage for intervention
and control, number of randomized patients, trial and treatment
duration, inclusion criteria, and sponsor), study population (e.g. age,
sex, weight, previous treatment, disease severity), and study results of
included trials were extracted using a standardized data extraction
form. Efﬁcacy and safety data were sought for one time point of long-
term treatment, deﬁned as a treatment of at least 24 weeks.
Outcomes were PASI 75 (primary), PASI 90, PGA ‘clear/almost
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clear’, reduction in mean DLQI, patients with at least one AE,
patients with at least one SAE, and withdrawal due to AE.
Data analysis
RRs with 95% CI for dichotomous data and MDs with 95% CI for
continuous data were calculated for each study comparison. The effect
estimates of the individual studies were pooled in the meta-analysis
using a random-effects model (Review Manager 5.3.4). Inconsistencies
among the estimates were quantiﬁed using the I2 test. Wherever
heterogeneity among the included studies was substantial (Higgins and
Green, 2011), study results were not pooled but presented individually.
Limited placebo-controlled data were available for long-term
treatment. Most of the placebo control arms did not continue beyond
the induction period of usually 12 to 16 weeks. However, to calculate
effect estimates, a placebo arm is necessary. Three included studies
provided placebo data for up to week 24. The long-term placebo data
of efﬁcacy outcomes from these three studies were pooled to calculate
a mean ‘placebo response’, which was used as a model for trials
without long-term placebo control. Placebo data at week 24 were
available for PASI 75, PASI 90, and PGA ‘clear/almost clear’ Table 1.
Quality of the evidence
The quality of the individual included trials was assessed using the
Cochrane Risk of Bias Tool (Higgins et al., 2011). The available
evidence and its quality were summarized using the GRADE
approach (Atkins et al., 2004) for each available outcome in each
comparison. Using the GRADEproﬁler software (Brozek et al., 2008),
GRADE evidence proﬁles were developed for each available
treatment comparison. The quality of the evidence for each
comparison was categorized into one of the four categories, from
‘very low’ (+ − − − ) to ‘high’ (+ + + +) based on the criteria risk of
bias, inconsistency, indirectness, imprecision, publication bias, and
large effects (Balshem et al., 2011). In addition to the general criteria
for risk of bias, the quality was downgraded by two points if imputed
placebo data were used for calculation of the effect estimate to reﬂect
the limited validity of the results. Likelihood of publication bias was
graded as ‘undetected’ for each outcome, although no analysis such
as funnel plots or statistical tests for asymmetry could be carried out
due to the small number of included studies for each comparison.
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